Novaliq announces phase 1 study for dry eye solution

Novaliq GmbH announced the commencement of a phase 1 study for CyclASol (cyclosporine solution) following U.S. and European patent approval of the solution for treating dry eye syndrome.CyclASol is a 0.05% clear cyclosporine solution that is available in multidose and preservative-free bottles, according to a company press release.